|
|
Vaccine Detail
|
WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine |
| Vaccine Information |
- Vaccine Name: WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007077
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Sugiyama, 2005)
- Detailed Gene Information: Click Here.
- Description: This is for Leukemia Cancer (NCT00725283). An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21 (Sugiyama, 2005; NCIT_C78865).
|
| Host Response |
|
|
| References |
NCIT_C78865: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78865]
NCT00725283: [https://clinicaltrials.gov/show/NCT00725283/]
Sugiyama, 2005: Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert review of vaccines. 2005; 4(4); 503-512. [PubMed: 16117707].
|
|
